Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ostuka Of Japan Ends IPO Debut 1.9 Percent Above Asking Price

This article was originally published in PharmAsia News

Executive Summary

Japan's Otsuka Holdings barely surpassed its highly touted initial public offering target, enough to make it the largest IPO on record for a pharmaceutical company

You may also be interested in...



Coronavirus Update: Can IL-6 Drugs Cut Deaths? Kevzara Trials Starts In Worst Hit Countries

A round up of news from around the biopharma sector and its efforts to meet the challenges posed by the coronavirus pandemic.

QUOTED. 31 March 2020. US FDA.

The US FDA published on 29 March an emergency temporary guidance that relaxes oversight of certain sterilizers, disinfectant devices and air purifiers intended to kill the SARS-CoV-2 virus. See what the agency said about it here.

Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies

Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.

UsernamePublicRestriction

Register

SC073807

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel